Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

TEVA Teva Pharmaceutical Industries Ltd

16,85

-0,44 (-2,54%)

07 Fev 2025 - Fechado

Atrasado em 15 minutos

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Teva Pharmaceutical Indu....

Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Teva Pharmaceutical Indu....

Notícias Teva Pharmaceutical Industries Ltd

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
Quarta, 29 de Janeiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Segunda, 27 de Janeiro de 2025 (2 semanas atrás) • GlobeNewswire Inc.

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Segunda, 13 de Janeiro de 2025 (4 semanas atrás) • GlobeNewswire Inc.

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Sexta, 10 de Janeiro de 2025 (4 semanas atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Quinta, 26 de Dezembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Segunda, 23 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Sexta, 20 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Terça, 17 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Quarta, 11 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Quinta, 5 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Quarta, 4 de Dezembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Segunda, 25 de Novembro de 2024 (2 meses atrás) • GlobeNewswire Inc.

Mais Notícias de Teva Pharmaceutical Industries Ltd

XS2675107929 20250929 12...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições